文献园地
更多
TheranosticsDevelopment of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment
International ImmunopharmacologySiglec-E deletion alters AT macrophages phenotypes, induces an inflammatory response, and adipogenesis during diet-induced obesity
Journal of Orthopaedic ResearchDepth-Wise Changes in Tibial and Femoral Human Knee Joint Cartilage at Different Severities of Osteoarthritis
品牌库
更多tranScrip Ltd
Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.
Abbott B.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.
Formatech, Inc. Company dissolved
At Formatech, we help make new drugs happen… at the speed of science! Formatech, founded in 1993, provides contract services that deliver unique solutions to our clients' product development and manufacturing challenges. Our service offerings include: preformulation and formulation development of all common dosage forms, lyophilization development, cell culture/fermentation process development, purification/downstream process development and aseptic fill and finish of liquid and lyophilized dosage units. We have had excellent results developing biotherapeutic products. Our accomplishments include developing many Ab formulations at concentrations in excess of 200 mg/mL and an orally bioavailable peptide formulation. Our aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and ICH conforming stability programs. Our team is accomplished at completing new projects successfully even when confronted with very aggressive timelines. Our regulatory history includes FDA inspections and three inspections by the MHRA (letters and certificate of GMP compliance received).
GUS Schweiz AG
We optimize your business processes GUS ERP GmbH, GUS Nordic ApS and GUS Schweiz AG provide GUS-OS Suite, a web-based ERP business solution that includes all industry functionalities and fulfills regulatory requirements. The companies are members of the GSG GENII Software Group (www.gsg-genii.com), which offers leading, industry-specific software solutions and services, explicitly for medium-sized companies and public administrations. With its industry knowledge and personal customer relationships, the group of companies is a trustworthy partner and expert advisor to its customers. It accompanies its customers through digitization and ensures that they are equipped for the future in a volatile environment. GENII, headquartered in Munich, Germany, has generated sales of approximately 340 million euros with around 2,400 employees. GENII is backed by Bregal Unternehmerkapital and Elvaston.
GUS ERP GmbH
As a long-standing partner of the process industry, the GUS Group combines business competence with industry expertise and offers with GUS-OS ERP one of the most comprehensive software offerings for companies in the pharmaceutical, biotechnology, cosmetics, food and beverage, chemical and logistics industries. The GUS Group provides comprehensive consulting services, carries out projects and sets up IT infrastructures. Our own development team ensures continuous software innovations and the alignment of the solution with the norms and standards in our target industries. Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here .
Dr. August Wolff GmbH & Co. KG
Dr. August Wolff GmbH & Co. KG Arzneimittel is a family owned research oriented company still located in Bielefeld, Germany. Dr. August Wolff GmbH & Co. KG is selling medicinal products, medical devices and cosmetic products like Linola and Vagisan in several European countries. Since its inception in 1905 Dr. August Wolff has maintained strong focus in collaborations with universities to foster research and development in their search for novel products.
生知快讯
最新资讯
更多
Breeding Science:作物分子育种与种质资源创新 投稿必备的影响因子、收录偏好与通关技巧
一、领域背景与期刊定位2024-2025年全球作物育种领域聚焦基因编辑种质创新、全基因组选择育种模型优化、气候适应性作物选育三大热点方向,投稿痛点突出:据2025年农业领域投稿调研数据,72%的育种方向论文拒稿源于研究定位偏差,纯基础分子机制研究或纯栽培技术研究与专业育种期刊收稿范围不匹配。《Breeding Science》由日

Oil Crop Science:油料作物遗传育种/油脂合成代谢/植物抗逆生物学投稿必备的影响因子、收录偏好与通关技巧
---1. 领域背景与期刊定位2024-2025年油料作物领域研究热点聚焦基因组编辑辅助高油优质种质创新、非生物胁迫应答分子机制、特种油料功能性成分开发三大方向,领域投稿痛点突出:72%的初投拒稿源于研究内容与综合农学期刊收稿范围不匹配,缺乏专属领域垂直期刊投递渠道^中科院文献情报中心 2025^。《Oil Crop Science》由中国

Open Geosciences:地球科学跨学科研究(含地质资源/水文地质/地理信息系统/气候模拟)投稿必备的影响因子、收录偏好与通关技巧
---一、领域背景与期刊定位2024-2025年地球科学领域核心研究热点集中在双碳目标下的地质碳封存机制、极端气候灾害的GIS(地理信息系统)预警、古气候重建与AI预测交叉方向,行业投稿痛点突出:据^中科院文献情报中心2025^调研,76%的地学跨学科研究首次投稿拒稿源于期刊领域匹配度不足,纯应用类地学成果难以匹配细分领域顶